Krystal Biotech Announces FDA Clearance of Investigational N

Krystal Biotech Announces FDA Clearance of Investigational New Drug Application for KB408 for the Treatment of Type 1 Alpha-1 Antitrypsin Deficiency

Krystal Biotech Announces FDA Clearance of Investigational New Drug Application for KB408 for the Treatment of Type 1 Alpha-1 Antitrypsin Deficiency

itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Pennsylvania , United States , Hubert Chen , Exchange Commission , Nasdaq , Drug Administration , Clinical Development , Krystal Biotech Inc , Orphan Drug Designation Granted , Investigational New Drug Application , Senior Vice President , Krystal Biotech , Private Securities Litigation Reform Act ,